LabCorp to Acquire Chiltern for Approximately $1.2 Billion

Published on: 

Applied Clinical Trials

LabCorp-global life sciences company-and specialty CRO, Chiltern, announced that LabCorp will acquire Chiltern in an all-cash transaction for approximately $1.2 billion. Following the completion of the transaction, Chiltern will become part of LabCorp’s Covance segment.

Read the full release here.